Jul 11, 2019 / 09:00AM GMT
Olav Hellebø,ReNeuron Group plc-CEO&Director
Good morning. Welcome to ReNeuron's preliminary results presentation for the year ended 31st of March, 2019. I'm Olav Hellebø; and with me is Michael Hunt, our CFO. And let's just jump into it.
So just a little warm up in case you don't know us. But looking at you, most of you will know this. We are a global leader in cell therapy. What we work on is allogeneic therapies. We have 2 assets in clinical trials. And we have a very good news flow for the next year or 2 coming up.
So here's a quick overview of the platform. Human retinal progenitor cells is a cryopreserved formulation that we are using in retinitis pigmentosa. We are in the Phase IIa study currently, and we'll get into more details on that.
CTX is an immortalized neural progenitor stem cell line. Again, cryopreserved. Enables us to conduct clinical trials in a more reasonable fashion, being able to ship and store these products. There are pretty good shipping containers available now so you can actually get it anywhere you
Full Year 2019 ReNeuron Group PLC Earnings Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers